GGrantIndex
← Search

BIOMARKER DEVELOPMENT FOR THE EVALUATION OF MAS AGONIST RASRX1902 IN AMYOTROPHIC LATERAL SCLEROSIS

$1,521,025FY2022Defense Health AgencyDOD

University Of Arizona, Tucson AZ

Investigators

View source on USAspending →
BIOMARKER DEVELOPMENT FOR THE EVALUATION OF MAS AGONIST RASRX1902 IN AMYOTROPHIC LATERAL SCLEROSIS · GrantIndex